Drug intelligence / Profile preview

bivalirudin + eptifibatide

Development stage: Unknown
Lead developer: LifeBridge Health
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

This combination therapy consists of bivalirudin, a direct thrombin inhibitor, and eptifibatide, a glycoprotein IIb/IIIa receptor antagonist. It is used as an anticoagulant and antiplatelet regimen during percutaneous coronary intervention (PCI) in patients with coronary artery disease. Bivalirudin works by binding directly to thrombin to prevent clot formation, while eptifibatide inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor. The combination was specifically studied by LifeBridge Health in the CLEAR PLATELETS-2 trial to evaluate its effects on periprocedural myocardial infarction, platelet reactivity, and clot strength compared to bivalirudin monotherapy in patients also receiving high-dose clopidogrel.

Brand names: AngiomaxIntegrilin
Other names: bivalirudin plus eptifibatide

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)F2 (Thrombin)

Beyond the preview

Go deeper on bivalirudin + eptifibatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalirudin + eptifibatide.

Explore the full profile